LivaNovaLIVN
Recorded

LivaNova UBS Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration32 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Ben BibleAnalyst

Welcome. With me today is Alex Shvartsburg and Phil Kowalczyk, CFO and Head of Strategy and EVP from LivaNova. My name is Ben Bible. Pleasure to be speaking with you all at the Global Healthcare Conference here in Palm Beach. Alex, Phil, thank you for coming.

Ben BibleAnalyst

Thanks for having us. To start things off, for those of you that don't know the company, can you help frame LivaNova, where it is today, and where it is heading?

Alex ShvartsburgCFO

Sure. LivaNova is a global healthcare company built on nearly five decades of experience. We have two very interesting components to our business. Our core business is in the cardiopulmonary space and epilepsy space. It's been a bit of a turnaround story for the company. We've come a long way in terms of transitioning our portfolio. Now we are strictly focused on these two core businesses, which are large, profitable, cash-generating businesses that actually fuel the investments into the next stage of our evolution with the near-term opportunity that we have with obstructive sleep apnea and then possibly getting into difficult-to-treat depression. Company has performed extremely well over the last three years. We've achieved double-digit growth each of the last three years. We continue to perform well this year, and we've taken guidance up significantly over the course of this year.

Alex ShvartsburgCFO

We operate in a very disciplined way in terms of driving top-line growth as we focus on margin expansion and cash generation. That continues to be kind of the North Star for us in terms of where we're going from here. I don't know if I missed anything, Phil.

Ben BibleAnalyst

No. Great. That's great. Well, let's dig into CP a little bit more, which you guys have made a big deal and talked a lot about your leadership in Oxys, leveraging what you've done in HLM market.

Ben BibleAnalyst

How do you view the competitive landscape today, and how do you view it in the context of signing the Thermo Fisher agreement, and what does that mean for you?

Alex ShvartsburgCFO

Cardiopulmonary business as a whole, right, competes in the kind of a $2 billion market segment. Historically has been growing at low single digits, but what we've seen over the last few years is it has accelerated. The market itself has accelerated. I think some of the demographics continue to drive market growth, but also, historically, the market was impacted by kind of the minimally invasive cardiac procedures. Now as that patient base continues to age, they're no longer good candidates for kind of the repeat procedures. So they come in for open heart procedures, and that's where we step in. We are in roughly, in terms of our market share from a capital equipment perspective, we're in 70% market share position. So we effectively, we're enrolled in 70% of the procedures from around the world.

Alex ShvartsburgCFO

Our capital equipment segment continues to grow with the launch of our Essenz product that we launched back in 2023 that has continued to fuel our growth. Then about two-thirds of our revenue base comes from the consumables part of the portfolio. That piece of it has The key component there is the oxygenator. We've grown our market share in that segment from about 30% to about 40% over the last couple of years. That's been sort of on the heels of our ability to improve supply. As I said, the market has historically grown at a slower pace, so when the market accelerated, really the industry wasn't prepared for it. While we have been investing in our capacity expansion, we haven't really seen that from our competitors.

Alex ShvartsburgCFO

We're also investing in innovation in this space that we can talk a little bit about as we launch our new products in 2028. But the capacity expansion, our investments there have really been fueling the growth on the consumable side. We're building enough capacity now to satisfy a market share position of nearly where we are from a capital perspective, 70%. We're not committing to that from a long-term growth perspective, but we think we have the opportunity to get there with the investments we have made.

Ben BibleAnalyst

That's great. The Thermo Fisher agreement, how does that play into it?

Alex ShvartsburgCFO

Yeah. So kind of the gating factor to our growth has been the critical component supply, and that being the fiber component, which is a key element of the oxygenator. So, that component has changed ownership over the last few years, started as a 3M product, which was ultimately spun out into Solventum's business, and then acquired last year by Thermo Fisher. So we have been working with Thermo Fisher to improve the supply. They've done a good job of supporting our production output over the last 12, 18 months. But there's more work to be done there, and they're actually investing in building out some of their own capacity, which will come online later in 2027, which will give us kind of unlimited supply, as I said, where there's a big opportunity for us to become much more competitive in this space.

Alex ShvartsburgCFO

To date, we've been largely serving our own customer base.

Alex ShvartsburgCFO

Yeah. Unlocking this supply really gives us an opportunity to kind of a license to hunt from a competitive perspective.

Ben BibleAnalyst

That's great. That's really exciting. Maybe if we could turn to epilepsy. VNS is very under-penetrated. How has the improved reimbursement in the long-term CORE-VNS study changed behavior in this market?

Phil KowalczykHead of Strategy and EVP

Yeah, it's a great question. It's an exciting time for our epilepsy business. We start with the market, maybe, to give you an appreciation for the opportunity in front of us. So you've got about 3 million, I'll use U.S. numbers, of patients with epilepsy. About 2 million of them get drugs, respond well, and kind of it's sufficient therapy. About 1 million don't. They're classified as drug-resistant epilepsy. Within those 1 million patients, we only see advanced therapies in about 10%. So this is a massively underserved patient population, and the average patient takes almost 15 years and cycles about seven drugs, even though they basically know those drugs won't work for them after they've been classified as DRE, before they get to that therapy.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day